Patents by Inventor Russell Dean Stucky

Russell Dean Stucky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 3-methyl-pyrrolidine-2,5-dione derivatives useful as CGRP receptor antagonists
    Patent number: 10336726
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: July 2, 2019
    Assignee: Eli Lilly and Company
    Inventors: Jennifer Anne McMahon, Miles Goodman Siegel, Russell Dean Stucky
  • 3-METHYL-PYRROLIDINE-2,5-DIONE DERIVATIVES USEFUL AS CGRP RECEPTOR ANTAGONISTS
    Publication number: 20180327384
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt or hydrate thereof, useful as a CGRP receptor antagonist.
    Type: Application
    Filed: May 8, 2018
    Publication date: November 15, 2018
    Inventors: Jennifer Anne McMahon, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP receptor antagonists
    Patent number: 9708297
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044138
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • 6-substituted nicotinamide derivatives as opioid receptor antagonists
    Patent number: 8101638
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Grant
    Filed: July 8, 2008
    Date of Patent: January 24, 2012
    Assignee: Eli Lilly and Company
    Inventors: Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20090023785
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diasteromers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Application
    Filed: July 8, 2008
    Publication date: January 22, 2009
    Inventors: Concepcion Pedregal-Tercero, Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080255152
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 16, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charies Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • 6-substituted nicotinamide derivatives as opioid receptor antagonists
    Patent number: 7399774
    Abstract: A compound of the formula (I) or a pharmaceutically acceptable salt, enantiomer, racemate, diastereomers or mixtures thereof, or a solvate thereof, formulations and methods of use thereof, as opioid receptor antagonists are disclosed wherein the variables are as described herein.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: July 15, 2008
    Assignee: Eli Lilly and Company
    Inventors: Miles Goodman Siegel, Russell Dean Stucky, Kumiko Takeuchi
  • Diaryl ethers as opioid receptor antagonist
    Patent number: 7381719
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: June 3, 2008
    Assignee: Eli Lilly and Company
    Inventors: Maria-Jesus Blanco-Pillado, Marta Garcia De La Torre, Nuria Diaz Buezo, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi
  • Beta3 adrenergic agonists
    Publication number: 20040242633
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula I: 1
    Type: Application
    Filed: May 4, 2004
    Publication date: December 2, 2004
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Gerd Ruehter, Daniel Jon Sall, Theo Schotten, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • &bgr;3 adrenergic agonists
    Patent number: 6730792
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: May 4, 2004
    Assignee: Eli Lilly and Company
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • Beta3 adrenergic agonists
    Publication number: 20030191156
    Abstract: The present invention relates to a &bgr;3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.
    Type: Application
    Filed: December 13, 2002
    Publication date: October 9, 2003
    Inventors: Britta Evers, Cynthia Darshini Jesudason, Rushad Eruch Karanjawala, David Michael Remick, Daniel Jon Sall, Miles Goodman Siegel, Wolfgang Stenzel, Russell Dean Stucky, John Arnold Werner
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6541497
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: April 1, 2003
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6353027
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: March 5, 2002
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.
  • Hypoglycemic and hypolipidemic compounds
    Patent number: 6194446
    Abstract: This invention provides compounds and their pharmaceutically-acceptable salts, pharmaceutical formulations of said compounds, and methods for treating hyperglycemia associated with non-insulin dependent diabetes and for treating hyperlipidemia.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: February 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Samuel James Dominianni, Margaret Mary Faul, Russell Dean Stucky, Leonard Larry Winneroski, Jr.